Akriti Jain, MD

SAN DIEGO — Akriti Jain, MD, highlights presentations from ASH Annual Meeting and Exposition focused on triplet combination therapy for patients with acute myeloid leukemia.

SAN DIEGO — Akriti Jain, MD, spoke with Healio about combination therapy with venetoclax for acute myeloid leukemia presented at ASH Annual Meeting and Exposition.

SAN DIEGO — In this video, Akriti Jain, MD, discusses a new targeted monotherapy being used for patients with acute myeloid leukemia, tuspetinib.

SAN DIEGO — In this video, Akriti Jain, MD, provides two updates on intensive treatment regimens for acute myeloid leukemia presented at ASH Annual Meeting and Exposition.

Healio spoke with Akriti Jain, MD, about the existing unmet needs in MDS patient care.

  Healio spoke with Akriti Jain, MD, about aproaching the treatment of myelodysplastic syndrome based on where patients lie on the MDS spectrum.

Healio spoke with Akriti Jain, MD, about the pre-MDS conditions that have the potential to progress into MDS if left untreated.

Healio spoke with Akriti Jain, MD, about recent diagnostic and treatment developments in MDS.

Healio spoke with Akriti Jain, MD, about the future of MDS research, specifically combination treatments like azacitidine and venetoclax.

In this video, Akriti Jain, MD, discusses whether patients with acute myeloid leukemia with IDH mutations should be treated with IDH inhibitors up front compared to venetoclaxcontaining regimens.